Clinical Research Directory
Browse clinical research sites, groups, and studies.
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to find out whether a pre-treatment PET scan using the experimental imaging tracer 18F-FAC can show how much of the standard chemotherapy for PDAC may be taken up by the cancer.
Official title: 18F-FAC PET Imaging to Quantify Gemcitabine Tumor Drug Uptake and Biodistribution in Pancreatic Cancer Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-11-18
Completion Date
2026-11-18
Last Updated
2025-09-04
Healthy Volunteers
No
Interventions
PET Scan
Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of \[18F\]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, New York, United States